Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol added to standard care for neonatal hypoxic-ischemic brain injury
2016-000222-19Phase 3Active
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asphyxia neonatorum and hypoxic-ischemic encephalopathy (HIE) comparing Allopurinol plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Death or severe neurodevelopmental impairment at 24 months. Started Jan 2017; status: active.
02
Drugs
allopurinol sodium
03
Conditions
asphyxia neonatorumhypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on 2016-000222-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000222-19.